Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?

समान संसाधन

• KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
  द्वारा: Lopez-Crapez, E, और अन्य
  प्रकाशित: (2010)
• High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease
  द्वारा: Ruzzo, Annamaria, और अन्य
  प्रकाशित: (2012)
• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
  द्वारा: Loupakis, F, और अन्य
  प्रकाशित: (2009)
• Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
  द्वारा: Gattenlöhner, S., और अन्य
  प्रकाशित: (2009)
• Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'
  द्वारा: Schirripa, M, और अन्य
  प्रकाशित: (2013)